Puma Biotechnology, Inc. is a biopharmaceutical company that develops and commercializes innovative cancer therapies. Its primary commercial product is NERLYNX (neratinib), an oral irreversible tyrosine kinase inhibitor approved in the U.S. for early stage and metastatic HER2-positive breast cancer. The company also in-licensed alisertib from Takeda, a selective Aurora Kinase A inhibitor under development for small cell lung cancer and hormone receptor-positive breast cancer.
expected 2027-02-04
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001437749-26-005891 | EDGAR | 108K words |
| 2025-02-27 | 2024-12-31 | 0001437749-25-005496 | EDGAR | 105K words |
| 2024-02-29 | 2023-12-31 | 0001437749-24-006121 | EDGAR | 103K words |
| 2023-03-02 | 2022-12-31 | 0001437749-23-005233 | EDGAR | 110K words |
| 2022-03-03 | 2021-12-31 | 0001437749-22-005164 | EDGAR | 103K words |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009840 | EDGAR | 93K words |
| 2020-02-28 | 2019-12-31 | 0001564590-20-007591 | EDGAR | 87K words |
| 2019-03-01 | 2018-12-31 | 0001564590-19-005830 | EDGAR | 88K words |
| 2018-03-09 | 2017-12-31 | 0001564590-18-005152 | EDGAR | 83K words |
| 2017-03-01 | 2016-12-31 | 0001564590-17-003090 | EDGAR | 71K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-09 | 2026-09-30 | 0001437749-26-035912 | EDGAR | 35K words |
| 2026-08-06 | 2026-06-30 | 0001437749-26-026311 | EDGAR | 35K words |
| 2025-11-06 | 2025-09-30 | 0001437749-25-033633 | EDGAR | 36K words |
| 2025-08-07 | 2025-06-30 | 0001437749-25-025470 | EDGAR | 36K words |
| 2025-05-08 | 2025-03-31 | 0001437749-25-015533 | EDGAR | 32K words |
| 2024-11-07 | 2024-09-30 | 0001437749-24-033955 | EDGAR | 34K words |
| 2024-08-01 | 2024-06-30 | 0001437749-24-024309 | EDGAR | 34K words |
| 2024-05-02 | 2024-03-31 | 0001437749-24-014395 | EDGAR | 30K words |
| 2023-11-02 | 2023-09-30 | 0001437749-23-030028 | EDGAR | 39K words |
| 2023-08-03 | 2023-06-30 | 0001437749-23-021972 | EDGAR | 39K words |
| 2023-05-04 | 2023-03-31 | 0001437749-23-012589 | EDGAR | 34K words |
| 2022-11-03 | 2022-09-30 | 0001437749-22-025787 | EDGAR | 42K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-05 | 0001437749-26-035279 | EDGAR | 5K words |
| 2026-08-06 | 0001437749-26-026282 | EDGAR | 4K words |
| 2026-02-26 | 0001437749-26-005869 | EDGAR | 4K words |
| 2025-11-06 | 0001437749-25-033604 | EDGAR | 4K words |
| 2025-08-07 | 0001437749-25-025463 | EDGAR | 4K words |
| 2025-06-24 | 0001437749-25-021153 | EDGAR | 16K words |
| 2025-06-13 | 0001437749-25-020321 | EDGAR | 1K words |
| 2025-05-09 | 0001437749-25-015648 | EDGAR | 1K words |
| 2025-05-08 | 0001437749-25-015514 | EDGAR | 3K words |
| 2025-02-27 | 0001437749-25-005477 | EDGAR | 5K words |
281 total filings indexed. 249 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001401667 |
| Ticker | PBYI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pumabiotechnology.com |
| Listed | 2012-03-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PBYI (~200 tokens, structured JSON with cryptographic provenance)